- Home
- RC vs ADCT Comparison
RC vs ADCT Comparison
Compare RC & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RC | ADCT |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.8M | 496.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RC | ADCT |
|---|---|---|
| Price | $2.24 | $4.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $5.75 | ★ $7.60 |
| AVG Volume (30 Days) | ★ 3.1M | 1.6M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 20.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $75,209,000.00 |
| Revenue This Year | N/A | $10.36 |
| Revenue Next Year | $32.94 | $3.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.35 |
| 52 Week Low | $2.32 | $1.05 |
| 52 Week High | $7.64 | $4.80 |
Technical Indicators
Market Signals| Indicator | RC | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 30.43 | 54.25 |
| Support Level | $2.37 | $3.15 |
| Resistance Level | $2.53 | $4.32 |
| Average True Range (ATR) | 0.13 | 0.38 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 3.45 | 75.60 |
Price Performance
Historical ComparisonAbout RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).